Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab Effects on Regulatory T Cells and Dendritic Cells in Psoriasis
jRCTs041200070Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of guselkumab in plaque psoriasis, sponsored by Janssen Pharmaceutical. Primary endpoints: Primary: Proportion of Treg subsets and dendritic cell subsets by PASI-defined response at 12 weeks and Correlation of PASI score changes with dendritic cell subsets. Started Jun 2021; status: completed.
02
Drugs
guselkumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCTs041200070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041200070.